Premium
Unveiling the Mysteries of Clopidogrel Metabolism and Efficacy
Author(s) -
Bonello L,
Bonello N,
Grosdidier C,
CamoinJau L
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.222
Subject(s) - clopidogrel , pharmacogenomics , clinical pharmacology , pharmacology , medicine , pharmacogenetics , platelet , drug , chemistry , aspirin , biochemistry , genotype , gene
Clopidogrel is an important antiplatelet agent, but a considerable variability in the biological effect of the drug has been observed. Additionally, patients with insufficient platelet reactivity inhibition following a loading dose (LD) of clopidogrel have a poor outcome. The mechanisms of variability are dependent on genetic polymorphisms of enzymes involved in clopidogrel metabolism. Paraoxonase 1 has been identified as the main determinant of the biological and clinical efficacy of clopidogrel. This finding could enable the use of pharmacogenomics to tailor antiplatelet agents. Clinical Pharmacology & Therapeutics (2011); 90 6, 774–776. doi: 10.1038/clpt.2011.222